Full Press Release Details
Insulet Reports Third Quarter 2019 Revenue of $192 Million, an Increase of 27% Year-Over-Year
ACTON, Mass.--(BUSINESS WIRE)--November 5, 2019--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod Insulin Management System (Omnipod System),
today announced financial results for the three months ended September 30, 2019.
Third Quarter Financial Highlights:
Third quarter revenue of $192.1 million, up 27%, compared to revenue of $151.1 million in the prior year, exceeds guidance of $174 to $181 million
Global Omnipod revenue of $177.2 million, an increase of 34%
U.S. Omnipod revenue of $109.5 million, an increase of 34%
International Omnipod revenue of $67.7 million, an increase of 35%
Drug Delivery revenue of $14.9 million, a decrease of 21%
Gross margin of 64.1%, down 340 basis points, in-line with expectations
Operating income of $17.0 million compared to operating income of $6.9 million in the prior year
Net income of $0.9 million, or $0.01 per diluted share, compared to a net income of $1.7 million, or $0.03 per share, in the prior year
Recent Strategic Highlights:
Received clearance from the FDA for an Alternate Controller Enabled (ACE) Infusion Pump, allowing the Omnipod DASH Insulin Management System (Omnipod DASH System) to be a part of an interoperable automated insulin delivery system, such
as the Omnipod Horizon Automated Insulin Delivery System
Executed a successful private placement of $800 million in principal amount of 0.375% Convertible Senior Notes due in 2026 and repurchased $345 million in principal amount of the existing 1.25% Convertible Senior Notes due in 2021
Completed the full market commercial launch of the Omnipod DISPLAY and Omnipod VIEW apps for use with the Omnipod DASH System
Installing second highly-automated manufacturing line at the Company's new U.S. facility, with production on this line expected to commence in 2020
"Building on our outstanding growth and progress, we again delivered strong financial and operational results," said Shacey Petrovic, President and Chief Executive Officer. "Consistent execution of our strategic imperatives combined with
Insulet's strong foundation will fuel our continued growth. We are raising our outlook for the full year 2019 and will continue to drive growth and value creation over the long term. Our team is focused on delivering life-changing innovation
to people living with diabetes around the world."
For the year ending December 31, 2019, the Company is raising its revenue guidance to a range of $722 to $730 million, representing growth of 28% to 29% (previously 24% to 27%). Revenue ranges by product line are:
U.S. Omnipod of $410 to $414 million, representing growth of 27% to 28% (previously 21% to 23%)
International Omnipod of $251 to $253 million, representing growth of 46% to 47% (previously 43% to 45%)
Drug Delivery of $61 to $63 million, representing a decline of 8% to 11% (previously a decline of 3% to 8%)
For the quarter ending December 31, 2019, the Company expects revenue in the range of $193 to $201 million, representing growth of 17% to 22%. Revenue ranges by product line are:
U.S. Omnipod of $116 to $120 million, representing growth of 25% to 29%
International Omnipod of $64 to $66 million, representing growth of 16% to 20%
Drug Delivery revenue of $13 to $15 million, representing a decline of 10% to 22%
Future results may be affected by changes in ongoing assumptions and judgments, and may also be affected by non-recurring, unusual or unanticipated charges, expenses or gains.
Insulet will host a conference call at 4:30 p.m. (Eastern Time) on November 5, 2019 to discuss the financial results and outlook. The link to the live call will be available on the Investor Relations section of the Company's website at
http://investors.insulet.com, "Events and Presentations", and will be archived for future reference. The call may also be accessed by dialing (844) 831-3022 for domestic callers or (315) 625-6887 for international callers, passcode 3163969.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform.
The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see
or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit:
Forward-Looking Statements:
The 2019 financial results contained in this news release are subject to finalization in connection with the preparation of the Company's Form 10-Q for the quarter ended September 30, 2019. This press release contains forward-looking
statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their
potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated.
These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Insulet's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or
implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: risks associated with the Company's dependence on its principal product platform, the Omnipod System; and the Company's ability to
design, develop, manufacture and commercialize future products; Insulet's ability to reduce production costs and increase customer orders and manufacturing volumes; adverse changes in general economic conditions; impact of healthcare reform
laws; Insulet's ability to raise additional funds in the future on acceptable terms or at all; supply problems or price fluctuations with sole source or third-party suppliers on which Insulet is dependent; the potential establishment of a
competitive bid program for conventional insulin pumps; failure by Insulet to retain key supplies and/or supplier pricing discounts and achieve satisfactory gross margins; international business risks; Insulet's inability to effectively
operate and grow the Company's business in Europe following the expiration of an agreement with the Company's former European distributor on June 30, 2018; regulatory, commercial and logistics risks associated with the Company selling its
products in Europe in light of the uncertainty related to the timing and terms of the separation of the United Kingdom from the European Union (Brexit); Insulet's inability to secure and retain adequate coverage or reimbursement from
third-party payors for the Omnipod System or future products and potential adverse changes in reimbursement rates or policies relating to the Omnipod System or future products; failure to retain key payor partners and their members; adverse
effects resulting from competition; technological change and product innovation adversely affecting the Company's business; changes to or termination of Insulet's license to incorporate a blood glucose meter into the Omnipod System or its
inability to enter into new license or other agreements with respect to the Omnipod System's current or future features; challenges to the future development of our non-insulin drug delivery product line; Insulet's ability to protect its
intellectual property and other proprietary rights; conflicts with the intellectual property of third parties, including claims that Insulet's current or future products infringe or misappropriate the proprietary rights of others; adverse
regulatory or legal actions relating to the Omnipod System or future products; failure of Insulet's contract manufacturers or component suppliers to comply with the U.S. Food and Drug Administration's quality system regulations; the potential
violation of the Foreign Corrupt Practices Act or any other international, federal or state laws prohibiting "kickbacks" or protecting the confidentiality of patient health information or other protected personal information, or any challenge
to or investigation into Insulet's practices under these laws; product liability lawsuits that may be brought against Insulet, including stemming from off-label use of its product; breaches or failures of its product or information technology
systems, including by cyberattack; reduced retention rates of our customer base; unfavorable results of clinical studies relating to the Omnipod System or future products, or the products of Insulet's competitors; future publication of
articles or announcement of positions by diabetes associations or other organizations that are unfavorable to the Omnipod System; the concentration of substantially all of Insulet's manufacturing operations at a single location in China and
substantially all of Insulet's inventory at a single location in Massachusetts; Insulet's ability to attract and retain personnel; Insulet's ability to manage its growth; fluctuations in quarterly results of operations; risks associated with
potential future acquisitions or investments in new businesses; Insulet's ability to generate sufficient cash to service all of its indebtedness; the expansion of Insulet's distribution network; Insulet's ability to successfully maintain
effective internal control over financial reporting; the volatility of the trading price of Insulet's common stock; risks related to future sales of its common stock or the conversion of any of the Convertible Senior Notes; potential
limitations on Insulet's ability to use its net operating loss carryforwards; anti-takeover provisions in its organizational documents; and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the
Securities and Exchange Commission in February 2019 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties
materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any
forward-looking statements.
| INSULET CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||
| (Unaudited; in thousands, except per share data) | 2019 | 2018 | 2019 | 2018 | ||||||||||||||
| Revenue | $ | 192,115 | $ | 151,076 | $ | 528,806 | $ | 398,916 | ||||||||||
| Cost of revenue | 69,035 | 49,107 | 182,612 | 139,060 | ||||||||||||||
| Gross profit | 123,080 | 101,969 | 346,194 | 259,856 | ||||||||||||||
| Operating expenses: | ||||||||||||||||||
| Research and development | 30,779 | 22,336 | 94,997 | 61,404 | ||||||||||||||
| Sales and marketing | 47,749 | 35,952 | 136,766 | 105,576 | ||||||||||||||
| General and administrative | 27,548 | 36,816 | 82,559 | 81,686 | ||||||||||||||
| Total operating expenses | 106,076 | 95,104 | 314,322 | 248,666 | ||||||||||||||
| Operating income | 17,004 | 6,865 | 31,872 | 11,190 | ||||||||||||||
| Interest expense and other, net | (9,423 | ) | (5,012 | ) | (17,703 | ) | (16,842 | ) | ||||||||||
| Loss on extinguishment of long-term debt | (6,451 | ) | - | (6,451 | ) | (10 | ) | |||||||||||
| Income (loss) before income taxes | 1,130 | 1,853 | 7,718 | (5,662 | ) | |||||||||||||
| Income tax expense | (278 | ) | (194 | ) | (1,086 | ) | (939 | ) | ||||||||||
| Net income (loss) | $ | 852 | $ | 1,659 | $ | 6,632 | $ | (6,601 | ) | |||||||||
| Net income (loss) per share: | ||||||||||||||||||
| Basic | $ | 0.01 | $ | 0.03 | $ | 0.11 | $ | (0.11 | ) | |||||||||
| Diluted | $ | 0.01 | $ | 0.03 | $ | 0.11 | $ | (0.11 | ) | |||||||||
| Basic weighted-average number of shares outstanding | 60,743 | 59,017 | 59,986 | 58,780 | ||||||||||||||
| Diluted weighted-average number of shares outstanding | 62,336 | 61,146 | 61,728 | 58,780 |
| INSULET CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||||
| (Unaudited; in thousands) | September 30, 2019 | December 31, 2018 | ||||||||
| ASSETS | ||||||||||
| Cash, cash equivalents and short-term investments | $ | 605,504 | $ | 288,946 | ||||||
| Accounts and unbilled receivable | 77,537 | 76,672 | ||||||||
| Inventories | 90,207 | 71,414 | ||||||||
| Prepaid expenses and other current assets | 20,653 | 24,254 | ||||||||
| Total current assets | 793,901 | 461,286 | ||||||||
| Long-term investments | 31,006 | 140,784 | ||||||||
| Property, plant and equipment, net | 355,865 | 258,379 | ||||||||
| Goodwill and other intangible assets, net | 52,547 | 50,029 | ||||||||
| Other assets | 35,071 | 18,266 | ||||||||
| Total assets | $ | 1,268,390 | $ | 928,744 | ||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||
| Accounts payable | $ | 21,245 | $ | 25,500 | ||||||
| Accrued expenses and other current liabilities | 92,037 | 90,157 | ||||||||
| Total current liabilities | 113,282 | 115,657 | ||||||||
| Convertible debt, net | 985,771 | 591,978 | ||||||||
| Other liabilities | 18,769 | 9,010 | ||||||||
| Total liabilities | 1,117,822 | 716,645 | ||||||||
| Stockholders' Equity | 150,568 | 212,099 | ||||||||
| Total liabilities and stockholders' equity | $ | 1,268,390 | $ | 928,744 |
Contacts
Investor Relations and Media Contacts:
Vice President, Investor Relations and Corporate Communications
Senior Manager, Investor Relations